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Abstract
Accurate prediction of healthcare costs is important for optimally man-
aging health costs. However, methods leveraging the medical richness
from data such as health insurance claims or electronic health records are
missing. Here, we developed a deep neural network to predict future cost
from health insurance claims records. We applied the deep network and
a ridge regression model to a sample of 1.4 million German insurants to
predict total one-year health care costs. Both methods were compared to
Morbi-RSA models with various performance measures and were also used
to predict patients with a change in costs and to identify relevant codes
for this prediction. We showed that the neural network outperformed
the ridge regression as well as all Morbi-RSA models for cost prediction.
Further, the neural network was superior to ridge regression in predicting
patients with cost change and identified more specific codes. In summary,
we showed that our deep neural network can leverage the full complexity
of the patient records and outperforms standard approaches. We suggest
that the better performance is due to the ability to incorporate complex
interactions in the model and that the model might also be used for pre-
dicting other health phenotypes.
1 Introduction
Health care expenditures are one of the biggest expenses in Germany and opti-
mally managing these cost has great economical importance. Therefore, meth-
ods for accurate patient-level prediction of future health care cost are needed to
provide the basis for decision making. As medical costs reflect the development
of health over time, and health in turn is influenced by many factors such as
social demographics, previous medical history, environmental influences, genet-
ics but also by random events such as accidents, predicting the future health
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Figure 1: Graphical abstract
is inherently challenging. Consequently, accurately predicting health cost is a
challenging problem. Existing work on prediction of health cost can be divided
into two categories [18]: (1) Rule based prediction methods, in which decision
rules of an algorithm to predict future costs are manually defined. The disad-
vantage of this approach is that it requires deep domain knowledge and that the
capability of resulting models to reflect complex relations in the data is limited.
(2) Supervised learning based methods (e.g. linear regression models, random
forests or support vector methods) that learn to predict future cost from the
data [2, 5, 7, 9, 12, 18]. These methods have the advantage that they are not
limited in their expressiveness as rule based methods are. However, they typi-
cally require large datasets for training. For training of these methods, health
insurance claims records are an appealing data source. They cover most of
the health care expenditures of the patients and have the advantage of having
sample sizes that allow fitting rich models. Additionally, they contain detailed
information on patients, such as the medical history and social demographic in-
formation. The challenges of this data is that it is high dimensional, that there
are many hidden interactions between variables, and that the data is often not
normally distributed [4]. The aforementioned supervised learning methods are
believed to typically not leverage the potential of population scale data to detect
complex patterns [19]. Recent developments in deep learning techniques, such
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as novel deep neural network architectures and numerical approaches to fit the
networks, promise to address some of these challenges. Deep learning has been
successfully applied in the medical domain to task such as dermatologist level
detection of skin cancer [8], prediction of various clinical outcomes from elec-
tronics health records [15], or the detection of diabetic retinopathy from retinal
fundus photographs [10], showing the potential of this technology.
We present a novel deep neural network architecture to predict future health
care cost from health insurance claims records (See Figure 1). This network
architecture allows to fully capture the richness of the medical data in health
insurance claims and can be fitted on a standard workstation with 64GB of
RAM. We compare it on health insurance claim records of ∼ 1.4 million patients
from German statutory health insurances against various standard methods
and show that it outperforms existing approaches. It also is better identifying
patients at risk than standard linear regression approaches. Finally, we show
how the parameters of the network can be interpreted and that the network
uses medically relevant features for its prediction.
2 Methods
2.1 Data
This study is based on data of the Institute for Applied Health Research Berlin
(InGef) database, which contains anonymised longitudinal claims data of more
than 60 German statutory health insurances. Claims data of the years 2010 to
2017 for a sample of about 1′403′346 insurants was used, which is representative
for the German population with respect to age, sex and state of residence.
Besides sociodemographic information, the database contains information on
hospital stays, outpatient physician visits, drug prescriptions and remedies and
aids including costs in each of the sectors. Further details of the database
can be found elsewhere [1]. An approval of an ethics committee or informed
consent of the patients was not required for the conduct of this study since all
patient- and provider-level information are anonymised to comply with German
data protection regulations and German federal law. In the remainder of this
manuscript we will refer to the period ranging from Q1 2010 to Q4 2015 as the
observation period and to the period from Q3 2016 to Q2 2017 as the evaluation
period.
2.2 Data Representations
The input for the machine learning algorithms was formatted in the follow-
ing manner: Each numerical value was kept as a feature. Dates were coded
in quarters since Q1 of 2010. Categorical values, such as International Statis-
tical Classification Of Diseases And Related Health Problems, 10th revision,
German Modification (ICD-10-GM) codes, Anatomical Therapeutic Chemical
(ATC) codes, Diagnosis Related Group (DRG) codes, German procedure clas-
sification (OPS), physician subject group key (FG) and schedule of fees for
physician outpatient services (GOP) codes or sex, were coded using a one-hot
encoding (i.e. if n possible categories k1, . . . , kn were possible, the observation
of category kj was coded by a n-dimensional vector that was 1 at the index j
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and 0 everywhere else). If multiple categories were observed in a quarter, the
representing vectors were added. This coding was performed for each quarter
and the resulting vectors were concatenated into a single vector of dimension
24*91’470 =2’491’470 representing the patient data in the observation period.
In order to accelerate model fitting, we only considered variables that had more
than 1′000 entries, leading to a vector of dimension 24*13’876 = 333’024.
2.3 Model definition
We used a model with four hidden layers (See Figure 2). The first four layers
had each 50 neurons. In the fourth layer the original input was concatenated
to the hidden vector and fed to the last layer, which had seven neurons to
predict seven cost categories (Medications, practice, hospital, medical sundries,
therapeutic appliances, compensation for incapacity to work and dentistry). All
layers used the ReLU-activation function [14] and a dropout [16] rate of 0.25
during training.
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Figure 2: Network architecture: Shown is the architecture of the proposed
deep neural network. Shown in (light grey) are the input features. Shown in
(dark grey) are the target variables of the network. The (white) nodes are the
internal nodes of the network.
We compared the deep learning model to three standard models. (1) The
average cost per year in the previous 6 years. (2) The costs in the last year
of the observation time. (3) A ridge regression with parameter λ = 0.1. For
model assessment, we predicted separately the seven (see above) different cost
domains. We then summed all predicted costs except the cost to compensate for
incapacity to work for model assessment, in order to make the cost comparable
to costs reported for the Morbi-RSA [5, 6]. Furthermore, we performed model
ensembling for the ridge regression and the neural network (i.e. the network as
trained five times and the predictions of all five models was averaged for the
final prediction.)
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2.4 Model fitting
For model fitting we used the first 903′346 patients (training set). During model
fitting, we minimized the l2-loss between the future and the predicted costs using
ADAM [11], which is an extension of stochastic gradient descent. Both the ridge
regression and the deep learning model was trained for 25 epochs. For training
of the ridge regression a batch size of 128 was used and for training of the neural
network a batch size of 32 was used.
2.5 Implementation
All models have been implemented in python and keras [3].
2.6 Evaluation Criteria
To assess the model quality, we determined the following quality criteria: Pear-
son’s correlation coefficient, Spearman’s correlation coefficient, the mean abso-
lute error and Cumming’s Prediction Measure. The performance was evaluated
on the subset of 357′239 of the 500′000 held out patients (test set) that where
alive in the observation period and either died or were still insured on at least
one day in the evaluation periods.
We further assessed how well the methods could be used to identify patients
with changing costs. As this is indicating a change of health status or treat-
ment, these patients could benefit from preventive interventions. To this end,
we divided our test set patients into three groups. Those for which the cost
decreased more than 100-fold between the last year of the observation period
and the first year of the prediction period; those for which the cost increased
more than 100-fold; and the remaining patients. In order to not include patients
with overall low cost in the two group (e.g to not include patients that change
from 0.01 to 10.0 Euro) that have strong cost changes, we added 10 Euros to
the overall cost before computing the fold change. We then computed the area
under the precision-recall curve (auPRC) for identification of patients with in-
creasing, resp. decreasing costs from all patients. To understand for which cost
range the respective methods performed best, we computed the error of the
prediction in dependence of the cost.
2.7 Sensitivity analyses
We investigated how the performance of the neural network depends on the
amount of available training data. To this end, we trained the model on
only 100′000, 200′000, 300′000, 400′000, 500′000, 600′000, 700′000, 800′000 and
900′000 patients. Furthermore, we investigated how the length of the observa-
tion time affects the predictive performance. Therefore, we trained the model
also for each of the patient sets using the data from one to six years up to the
end of the observation period.
2.8 Feature identification
An important application of predictive models is to identify relevant features in
the data and to understand their effect on the prediction. This allows for exam-
ple to identify and quantify risk factors. A common approach in linear models
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r ρ MAPE r2 CPM
Spendings in last year 0.418 0.551 2403.30 -0.005 0.191
Mean of previous spendings 0.464 0.547 2078.76 0.200 0.301
Ridge regression 0.514 0.610 2126.03 0.260 0.285
Neural network 0.524 0.631 2013.35 0.264 0.323
Ridge regression (ensemble) 0.517 0.611 2116.67 0.265 0.288
Neural network (ensemble) 0.527 0.632 2004.33 0.266 0.326
Morbi-RSA model (2018)∗ na na 2267.60 0.258 0.242
Morbi-RSA full model∗ na na 2233.53 0.263 0.253
Table 1: Performance assessment. Evaluation of methods using: Pear-
son’s correlation (r), Spearman’s correlation (ρ), mean absolute prediction error
(MAPE), R squared (r2) and Cumming’s Prediction Measure (CPM). Perfor-
mance for the Morbi-RSA models on a different data set (∗) where obtained
from [5, 6]. Correlation values where not available (na) for these models.
is to identify the weights that have a large absolute value as they correspond
to the features that have as strong impact on the prediction. For deep neural
networks it has been shown that this strategy is suboptimal [17] as it does not
capture the interactions between features that the neural network uses. Here,
we therefore used a strategy called integrated gradients [17] that is more robust.
We determined the average integrated gradients of all patients in the evaluation
set. Furthermore, we divided the mean integrated gradient by the number that
the actual feature was nonzero, to account for the fact that not all features are
equally abundant. We did not show codes in the results that allow identification
of health insurance companies which contributed to the study database.
3 Results
To establish a baseline, we first compared the performance of all methods to
predict costs. We found that the neural network was able to better predict future
costs than ridge regression or the other two standard models in all considered
measures as shown in Table 1. Furthermore, we found that ensembling several
training runs provides an additional small improvement.
To better understand in which cost regimes the neural network and the
ridge regression performed better, we studied the average absolute error in Eu-
ros depending on the true costs. The neural network performed better for
patients with total costs lower than ∼ 10′000 Euro, whereas the ridge regres-
sion performed better for patients who were more expensive (See Figure 3a and
Figure 3b).
As sensitivity analyses, we studied how the number of samples in the train-
ing set and the length of the observation period affect the performance of the
prediction for the neural network. Our analyses showed that as the number of
patients increased the predictive performance , as measured by R2, increased.
The same was true when the observation time increased (See Figure 4a). A
similar picture can also be seen for the Spearman and Pearson correlation (See
Supplementary Figure S1). We compared this to the performance of the ridge
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Figure 3: Error analysis: Shown is the histogram of total cost (a), the log10
absolute error based on the true cost of the ridge regression and the neural
network (b) as well as the difference between the neural network error and the
ridge regression error (c)
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Figure 4: Dependence of performance on patient number and obser-
vation time: Shown is the performance (r2) of the neural network depending
on the patient number and the length of the observation period in years (a).
Shown in (b) is the difference between the r2 of the neural network and of the
ridge regression.
regression (See Figure 4b). We found that at 100′000 patients the r2 of the neu-
ral network was lower than for the ridge regression but that for larger sample
sizes the neural network had in general a higher r2.
Next, we analysed the ability of identifying patients with changing costs
(Figure 5a and Figure 5b). In this analysis, we did not consider the model that
used the last years costs as prediction for the future costs as costs are predicted
to stay constant for this model. The results of the analysis in predicting pa-
tients with increasing/decreasing costs are shown in Figure 5c and Figure 5d,
respectively. We found that overall, prediction of decreasing costs was easier
than increasing costs. Furthermore, we found that for both direction of the cost
change the neural network outperformed the ridge regression. For increasing
costs the neural network had an auPRC of 0.08 while the ridge regression only
had an auPRC of 0.04. For decreasing costs the neural network at an auPRC
of 0.24 while the ridge regression had an auPRC of 0.21. A similar picture also
emerged for the area under the ROC curve where the neural network had an
auROC of 0.93 and 0.90 for decreasing and increasing costs, respectively. Here
the ridge regression had an auROC of 0.93 and 0.86 for decreasing and increas-
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Figure 5: Cost change prediction: Shown are the raw cost (a) in the last
year of the observation period (current costs) and the evaluation period (Future
costs) as well as the log10 fold-change between them (b). Shown in (c)-(d) are
the precision recall curves for predicting increasing and decreasing costs.
ing costs, respectively. For both measures the Ridge regression and the neural
network were substantially better than the baseline methods that did not model
the costs.
Finally, we studied via integrated gradients, on which features of the data the
neural network based its prediction and how this differed from the features used
by the ridge regression. We first determined the importance of features from
different quarters in the observation period by summing the integrated gradients
of all feature in a quarter. We found that both methods have a similar temporal
distribution of the importance and that for prediction the most recent features
were the most important (See Figure 6).
To evaluate whether the features showed a qualitative difference between the
neural network and the regression, we identified the features with the highest
(associated with higher cost) integrated gradient in set of patients that have
an 100-fold increase in costs. To this end, we summed the integrated gradients
of each code over all quarters in the observation period. The top-20 codes are
shown in Table 2 for the neural network and for the ridge regression in Table 3.
We found that the neural network relied more on ICD10 diagnosis and ATC
medication code than the ridge regression (8 of 20 vs. 3 of 20).
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Code Short description IG
Sex Male Male patient 0.017
GOP key 01321 Treatment by non health insurance-
accredited physicians
0.014
GOP key 03004 Practitioner care of patients with age be-
tween 55 and 75 years
0.014
GOP key 03220 Treatment of a patient with at least one
life-changing chronic disease
0.012
ICD10 key F102 Alcohol dependence 0.011
Sex Female Female patient 0.011
GOP key 03221 Treatment of a patient with at least one
life-changing chronic disease
0.010
GOP key 03005 Practitioner care of patients older than 75
years
0.010
ICD10 key F171 Mental and behavioural disorders due to
use of tobacco
0.009
ICD10 key M171 Unilateral primary osteoarthritis of knee 0.009
ATC code B01AC04 Clopidogrel (antithrombotic agent) 0.009
GOP key 03004R Practitioner care of patients with age be-
tween 55 and 75 years
0.009
GOP key 32001A Profitability bonus for arranging and pro-
viding laboratory services
0.008
GOP key 01731 Early detection of cancer in men 0.008
ICD10 key M4809 Spinal stenosis 0.008
ICD10 key G359 Multiple sclerosis 0.008
OPS key 80103 Application of drugs and electrolyte solu-
tions via the vascular system in newborns
0.007
ATC code N06AX16 Venlafaxine (antidepressants) 0.007
GOP key 32001B Profitability bonus for arranging and pro-
viding laboratory services
0.007
GOP key 07220 Surgical primary care 0.007
GOP key 06222 Basic ophthalmic care 0.007
ICD10 key M545 Low back pain 0.007
ICD10 key F430 Acute stress reaction 0.007
Table 2: Codes with the highest feature importance as determined by the
integrated gradients (IG) for the neural network, as well as a description of the
codes
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Code Short description IG
GOP key 03220 Treatment of a patient with at least one life-changing
chronic disease
0.020
GOP key 03221 Treatment of a patient with at least one life-changing
chronic disease
0.017
Sex Male Male patient 0.016
Sex Female Female patient 0.015
GOP key 03004R Practitioner care of patients with age between 55 and
75 years
0.014
GOP key 03004 Practitioner care of patients with age between 55 and
75 years
0.013
GOP key 03040 Family medical care 0.013
GOP key 03230 Problem-oriented medical consultation, which is nec-
essary due to the nature and severity of the illness
0.010
ATC code V04CA02 Tests for diabetes (Glucose) 0.010
GOP key 03111R Practitioner care of patients with age between 5 and
59 years
0.007
ATC code M01AE01 Ibuprofen (antiinflammatory and antirheumatic) 0.007
ICD10 key F171 Mental and behavioural disorders due to use of to-
bacco
0.007
Hospital type Hospitals of maximum care 0.006
GOP key 32001J Profitability bonus for arranging and providing lab-
oratory services
0.006
GOP key 03040G General practitioner medical care 0.006
GOP key 32001A Profitability bonus for arranging and providing lab-
oratory services
0.006
FG key 53 Physician group: Neurology 0.005
GOP key 32094 Quantitative determination of glycated hemoglobins 0.005
GOP key 03212 Chronic disease 0.005
FG key 11 Physician group: Trauma Surgery 0.005
GOP key 01321 Treatment by non health insurance-accredited physi-
cians
0.005
Table 3: Codes with the highest feature importance as determined by the
integrated gradients (IG) for the ridge regression, as well as a description of the
codes
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Figure 6: Importance of features per quarter: Shown is the summed
normalized integrated gradient (Importance) per year for the ridge regression
and the neural network.
4 Discussion
Accurate prediction of future health care cost provides the basis to optimally
manage healthcare costs. Furthermore, identification of patients whose cost will
change allows optimization of interventions given a limited budget in order to
improve population health. To achieve this it is important to have accurate
predictions of the future health costs. In this work we presented a deep learning
based approach to predict future costs. Our approach can leverage the full
complexity of the patient records and does not require prior feature selection.
We showed that our approach can outperform standard approaches, includ-
ing the Morbi-RSA for all measured performance metrics (See Tab.1). We sug-
gest that the performance gain is due to two reasons. First, our approach learns
important features from the data and does not require manual feature selection.
It has been shown that learnt features allow better predictions in computer
vision and speech processing given enough training data [13]). The value of
learning predictive features from the data is suggested by the better (state-
of-the-art) performance of our implementation of ridge regression compared to
the existing implementation of Morbi-RSA that is only based on 80 diseases.
Second, our deep learning approach allows modelling of complex interactions
between all variables which is not possible for ridge regression. This enables
better modelling of medical phenotypes such as interactions between age, sex
and diagnosis. This is supported by the identified terms that are associated with
increasing costs between ridge regression and the deep neural network, where
the ridge regression uses mainly the GOP codes and the deep network puts a
higher emphasis on medical diagnoses and prescribed drugs. It also worth not-
ing that in contrast to the Morbi-RSA, which is mainly based on ICD10 codes,
both the ridge regression and the neural network rely on GOP codes.
Since we placed no strong assumption on the phenotype that we modelled, we
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believe that the neural network may also easily adapted to predict other medical
phenotypes. However, we also acknowledge that further research is necessary to
better understand the merits and limits of deep learning in identifying medical
phenotypes from insurance claims. This includes the optimal architecture of the
networks but also strategies to interpret deep networks, to provide uncertainty
estimates for the models and model distribution shifts caused by changes in
billing and treatment guidelines.
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Supplementary Figure 1: Dependence of performance on patient
number and observation time: Shown is the performance (Pearson’s corre-
lation (r), Spearman’s correlation (ρ), mean absolute prediction error (MAPE),
R squared (r2) and Cumming’ s Prediction Measure (CPM) of the neural net-
work depending on the patient number and the length of the observation period
in years.
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